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Abstract
Background: The corpus luteum (CL) is a transient endocrine gland and prostaglandin F2-alpha is considered to
be the principal luteolysin in pigs. In this species, the in vivo administration of prostaglandin F2-alpha induces
apoptosis in large vessels as early as 6 hours after administration. The presence of the prostaglandin F2-alpha
receptor (FPr) on the microvascular endothelial cells (pCL-MVECs) of the porcine corpus luteum has not yet been
defined. The aim of the study was to assess FPr expression in pCL-MVECs in the early and mid-luteal phases (EL-
p, ML-p), and during pregnancy (P-p). Moreover, the effectiveness of prostaglandin F2-alpha treatment in inducing
pCL-MVEC apoptosis was tested.
Methods: Porcine CLs were collected in the EL and ML phases and during P-p. All CLs from each animal were
minced together and the homogenates underwent enzymatic digestion. The pCL-MVECs were then positively
selected by an immunomagnetic separation protocol using Dynabeads coated with anti-CD31 monoclonal
antibody and seeded in flasks in the presence of EGM 2-MV (Microvascular Endothelial Cell Medium-2). After 4
days of culture, the cells underwent additional immunomagnetic selection and were seeded in flasks until the
confluent stage.
PCR Real time, western blot and immunodetection assays were utilized to assess the presence of FPr on pCL-
MVEC primary cultures. Furthermore, the influence of culture time (freshly isolated, cultured overnight and at
confluence) and hormonal treatment (P4 and E2) on FPr expression in pCL-MVECs was also investigated.
Apoptosis was detected by TUNEL assay of pCL-MVECs exposed to prostaglandin F2-alpha.
Results: We obtained primary cultures of pCL-MVECs from all animals. FPr mRNA and protein levels showed
the highest value (ANOVA) in CL-MVECs derived from the early-luteal phase. Moreover, freshly isolated MVECs
showed a higher FPr mRNA value than those cultured overnight and confluent cells (ANOVA). prostaglandin F2-
alpha treatment failed to induce an apoptotic response in all the pCL-MVEC cultures.
Conclusion: Our data showing the presence of FPr on MVECs and the inability of prostaglandin F2-alpha to
evoke an in vitro apoptotic response suggest that other molecules or mechanisms must be considered in order
to explain the in vivo direct pro-apoptotic effect of prostaglandin F2-alpha at the endothelial level.
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Background
The corpus luteum (CL) is a transient endocrine gland
essential for the regulation of ovarian cycles as well as for
establishing and maintaining pregnancy. Prostaglandin
F2α  (PGF2α) is considered the principal luteolysin in
domestic animals and acts on target cells [1] by means of
a specific plasma membrane-associate receptor, prostag-
landin F2-alpha receptor (FPr). The FPr was detected on
steroidogenic luteal cells [2-5] but its presence on other
target cells could not be excluded.
Our previous data [6] showed that, in a porcine CL regres-
sion model, cloprostenol (a PGF2α synthetic analogue)
first induces apoptosis of luteal endothelial cells then
apoptosis of steroidogenic cells and suggest that the struc-
tural regression of the CL may begin with an early
response of the endothelial compartment to PGF2α. This
hypothesis relies on the assumption that FPrs are present
on endothelial cells (ECs). The expression of the FPr was
described by RT-PCR in bovine ECs derived from CLs [7];
on the contrary, FPr mRNA has been identified only on
swine steroidogenic cells by an in situ study [8]. Therefore,
to date, the presence of the FPr on luteal ECs is not fully
clarified, perhaps due to the different techniques utilized.
The porcine CL is not sensitive to the luteolytic stimulus
until day 12 of the cycle [9-11]. Luteal PGF2α binding sites
increase during CL formation reaching a maximum on
day 13 of the oestrous cycle, concurrently with the onset
of luteal sensitivity to PGF2α [3,12]. Limited data exist
confirming that an FPr increase is responsible for the
acquisition of luteolytic sensitivity.
The importance of the interaction between luteal cells and
ECs was demonstrated both in in vivo and in vitro experi-
ments in bovine and swine species [13-17].
The interest in EC biology increased in parallel with the
optimization of successful protocols for their isolation
and culture, allowing the study of EC involvement in
many different physiological or pathological processes.
EC isolated from large vessels or from tissue microvascu-
lature show a morphological heterogeneity [18,19] and
significant functional differences [20]. Additional differ-
ences have been observed among EC isolated from micro-
vessels of different organs [21,22] as well as from different
regions of the same organ [23-25]. These differences are
mainly due to the local micro-environment (e.g., the pres-
ence of matrix proteins, soluble cytokines, growth factors
and paracrine signals) and to cell-to-cell communication.
In this context, the isolation and characterization of pCL-
MVECs may lead to a better insight into endocrine gland
physiology and contribute to explaining some physiolog-
ical differences during the CL lifespan.
Many studies have been focused on the CL-MVEC isola-
tion in different species [23,26-31] except swine where
MVEC isolation has been described only in the fetal
organs [32] and the heart [33].
In order to obtain pure MVEC cultures from CLs at differ-
ent stages (early and mid-luteal phases and during preg-
nancy), the initial aim of the present study was to define
a reliable isolation method. Thus, our subsequent aims
were to investigate the presence of the FPr, both at the
mRNA and the protein level, on pCL-MVEC and to verify
if PGF2α treatment is effective in inducing pCL-MVEC
apoptosis.
Materials and methods
pCL-MVEC culture set-up
Animals and corpora lutea collection
Twelve prepubertal Large White gilts (94 ± 1.47 Kg body
weight) were injected i.m. with 1250 iu (international
units) of equine chorionic gonadotropin (eCG; Folligon-
Intervet, Holland) and, 60 h later, with 750 iu of human
chorionic gonadotropin (hCG; Corulon-Intervet) to syn-
chronize ovulation. The animals were randomly assigned
to three groups (n. = 4). Four animals were artificially
inseminated at 40/44 h post-hCG treatment and preg-
nancy was determined after 30 days by ultrasonography.
The ovaries were surgically removed from all animals: 4 at
the early luteal phase (EL-p: 6 days after ovulation), 4 at
the mid-luteal phase (ML-p: 12 days after ovulation) and
4 during the pregnancy phase (P-p: 60 days of pregnancy).
All animals were housed and used according to EEC ani-
mal care guidelines. The experimental procedures had
previously been submitted to and approved by the Ethical
Committee of Bologna University.
Isolation and culture conditions of Microvascular Endothelial Cells 
(MVECs)
The ovaries were immediately taken to the laboratory in
ice-cold DPBS (Dulbecco Phosphate Buffer Saline; Cam-
brex Bio Sciences, Verviers, Belgium) and washed several
times in sterile DPBS; the corpora lutea (CLs) were then
isolated under sterile conditions.
All CLs from each animal (14.1 ± 5.9) were cut into small
fragments (~1 mm3) with a razor blade and minced
together with a pestle and mortar. Small aliquots (100 µg)
of homogenate were immediately frozen in liquid nitro-
gen for RNA extraction, and protein and progesterone (P4)
analyses. The remaining homogenate was washed (3
times) by adding sterile DPBS (1:3, w:v) and centrifuged
(500 × g, 5 min). The final pellet was resuspended in ster-
ile DPBS containing collagenase (2 mg/ml; type IA [420
U/mg]; Sigma Chemical Company, St. Louis, MO, USA),
BSA (4 mg/ml; Fraction V, Sigma) and DNase I (0.02 mg/Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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ml; [1.87 U/mg]; Sigma). After 20 min on a rocking plat-
form (200 rpm) at 37°C, enzymatic digestion was
stopped by adding FBS (Foetal Bovine Serum, Gibco-Inv-
itrogen, Paisley, UK) (1:1, v/v); the suspension was fil-
tered (pore sizes: 280 µm; Sigma) and placed on ice, then
centrifuged (800 × g, 20 min) and resuspended in DPBS-
BSA (0.1%; w/v) at a final concentration of 5 × 105 cells/
ml (Thoma chamber counting). The pCL-MVECs were
then positively selected by an immunomagnetic separa-
tion protocol using Dynabeads® coated with anti-CD31
monoclonal antibody (Invitrogen), according to the man-
ufacturer's instructions. Briefly, the cells were mixed with
Dynabeads® to give a ratio of 5 × 105 cells/4 × 108 beads/
ml and were then incubated for 20 min at 4°C on a rock-
ing platform.
After incubation, the suspension was diluted (1:3, v/v)
with DPBS-BSA (0.1%), endothelial cells were then
exposed to Magnetic Particle Concentrators (DYNAL
MPC®, Invitrogen) for 2 min and washed five times in
DPBS-BSA.
The last resuspension was carried out in EGM™2-MV
medium (Microvascular Endothelial Cell Medium-2,
Cambrex); cell viability was determined using the Trypan
Blue exclusion test and viable cell density was calculated
using a Thoma chamber.
The pCL-MVECs (3 × 105 viable cells/flask) were then
placed in a T-25 tissue culture flask (Falcon, Beckton-
Dickinson, Franklin Lakes NJ, USA) in EGM™2-MV sup-
plemented with BulletKit® (Cambrex) in an humidified
atmosphere at 5% CO2 (38.5°C). After 4 days of culture,
the cells were trypsinized (Trypsin-EDTA solution, Sigma)
for 6 min at 37°C, further selected with Dynabeads® and
seeded again in EGM™2-MV supplemented with Bullet-
Kit®. At the 5th day of culture, the medium was substituted
by Human Endothelial-SFM (HE-SFM; Gibco-Invitrogen)
supplemented with 15% FBS (Gibco-Invitrogen) and 1%
antibiotic/antimicotic solution (Gibco-Invitrogen); the
medium was changed every 24 h until confluence. The
cultures were observed daily using phase-contrast inverted
microscopy (Nikon Eclipse TS100).
In addition, freshly isolated (dispersed) and overnight
(ON) cultured of ML-p pCL-MVECs were recovered; in
order to test the microenvironmental effects of steroid
hormones, the ML-p pCL-MVECs were cultured in com-
plete HE-SFM medium with and without hormones (P4,
10-6 M; Sigma Cod. P0130; 17β-estradiol [E2], 10-8 M;
Sigma Cod. E8875) until confluence.
Confluent cultures of porcine Aorthic Endothelial Cells
(pAEC) (8th passage) were assessed [34] at the same time.
Progesterone assay
Tissue P4 levels were determined as previously described
by Ribeiro et al. [35]. A small amount of frozen CL
homogenate (for each animal) was further homogenised
by Ultra Turrax in PBS (0.1 g/ml) in an ice bath. An aliq-
uot (20 µl) was extracted with petroleum ether (1 h at RT
on a rotary shaker) and centrifuged. The ether was then
collected and dried under a N2 stream. The dried ether
extract was resuspended in PBS (1 ml), diluted 1:50 and
an aliquot of 50 µl was then assayed using a validated
Radio Immuno Assay (RIA) [36]. The P4  results are
expressed as ng/mg tissue. The intra- and inter-assay coef-
ficients of variation were 5.2 % and 9 %, respectively.
Characterization of pCL-MVEC cultures
Cells were grown in slide chambers (8 well Culture Slide,
Falcon™, Becton-Dickinson) for 24 h and immunostained
for endothelial cell markers (factor VIII, CD31). The slides
were fixed with ethanol/acetic acid (2:1), washed with
PBS three times and blocked with 10% (v/v) FBS in PBS
for 1 h at RT. Primary antibodies, 1:200 rabbit anti-
human Factor VIII (A0082, Dako A/S, Glostrup, Den-
mark) or 1:100 mouse anti-porcine CD31 (MCA1746,
Serotec LTD, Oxford, UK), were added for 1 h at RT; then,
after several washings with PBS, secondary fluorescein iso-
thiocyanate (FITC)-conjugated antibodies were added
(1:800 in DPBS). Negative controls without primary anti-
bodies were performed.
The cells were counterstained with propidium iodide (PI)
and examined under an epifluorescence microscope
(Eclipse E600, Nikon, Japan) with fluorescein (FITC) and
tetramethylrhodamine (TRITC) filters using a Nikon dig-
ital camera. A minimum of 100 cells was evaluated in
each experimental sample.
To evaluate the presence of contaminant steroidogenic
luteal cells, a PCR Real time amplification for Steroidog-
enic acute regulatory protein (StAR) [37] was conducted
on pCL-MVEC cultures, as described below.
Identification of FPr
RNA extraction and Real time PCR
Total RNA was extracted from endothelial cells (pCL-
MVECs and pAECs) using RNeasy Mini Kits 50 (Qiagen
Sciences Inc, MD, USA) and was treated with an RNase-
free DNase set (Qiagen) according to the manufacturer's
instruction. Total RNA was extracted from tissue CL
homogenates using a TRIZOL isolation reagent (Invitro-
gen) according to the manufacturer's instructions.
Purified RNAs were resuspended in 25 µl of RNAse-free
water and spectrophotometrically quantified (A260 nm);
their quality was checked by gel electrophoresis on 2%
agarose gel. One microgram of total RNA was reverse-tran-Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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scribed to cDNA using an iScript cDNA Synthesis Kit (Bio-
RAD Laboratories Inc., California, USA) for a final volume
of 20 µl. Transcription reactions without reverse tran-
scriptase were performed in order to check for possible
DNA contamination.
Swine primers (FPr, StAR, HPRT [Hypoxanthine phos-
phoribosyltransferase]) were designed to span one intron,
to avoid genomic DNA amplification, using Beacon
Designer 2.07 Software (Premier Biosoft International,
Palo Alto, CA, USA). Primer sequences, expected PCR
product lengths and sequence accession numbers are
shown in Table 1.
Real-time quantitative PCRs were performed in the iCy-
cler Thermal Cycler (Bio-RAD) using SYBR green I detec-
tion. A master-mix of the following reaction components
was prepared to indicate end-concentrations: 0.5 µl for-
ward primer (0.2 µM), 0.5 µl reverse primer (0.2 µM), 9 µl
water and 12.5 µl IQ SYBR Green BioRad Supermix (Bio-
RAD Laboratories Inc.). cDNA (2.5 µl) was added to the
master mix (22.5 µl). All samples were assayed in dupli-
cate. The real-time PCR protocol employed was the fol-
lowing: initial denaturation for 3 min at 95°C, 40 cycles
at 95°C for 15 sec and 60°C for 30 sec, followed by a
melting step from 55° to 95°C with a rate of 0.5°C/s. The
housekeeping gene HPRT data were used to normalize the
RNA amount in all samples.
Real-time efficiency for each primer set was acquired by
amplification of a standardized cDNA dilution series. The
specificity of the amplified PCR products was verified by
melting curve analyses and an agarose gel electrophoresis
run. The housekeeping gene HPRT was used to normalize
the amount of RNA. FPr mRNA expression was calculated
as ∆CT (HPRT CT - FPr CT) [38] for all samples.
Protein extraction and Western Blot
The protein contents of CL homogenates and endothelial
cell lysates (sonication in PBS, 1 × 106 cells/200 µl) were
determined by a protein assay kit (Sigma). Protein aliq-
uots (20 µg) were separated on NuPage 10 % Bis-Tris Gel
(Invitrogen) for 50 min at 200 V and were then electro-
phoretically transferred onto a nitrocellulose membrane.
The blots were washed in PBS, and protein transfer was
checked by staining the nitrocellulose membranes with
0.2 % (w/v) Ponceau Red and gels with Comassie Blue.
Non-specific protein binding on the nitrocellulose mem-
brane was blocked with 5 % (w/v) milk powder in PBS-
T20 (phosphate buffer saline – 0.1 % (v/v) Tween-20) for
1 h at RT. The membranes were then incubated with a
1:500 dilution of a rabbit anti-FPr (NLS 1049, Novus Bio-
logicals Inc, Littleton, CO, USA) in TBS-T20 (20 mM Tris-
HCl, pH 7.4; 500 mM NaCl; 0.1 % Tween-20) with 0.5 %
milk overnight (O/N) at 4°C. After several washings with
PBS-T20, the membranes were incubated with the second-
ary biotin-conjugated antibody (1:80 000) and then with
a 1:1000 dilution of an anti-biotin horseradish peroxidase
(HRP)-linked antibody. Western blots were developed
using a chemiluminescent substrate (Pierce Biotechnol-
ogy Inc, Rockford, IL, USA) according to the manufac-
turer's instructions. The membranes were stripped and
reprobed by rabbit anti-HPRT (1:250; FL218, Santa Cruz
Biotechnology Inc, Santa Cruz CA, USA) in order to nor-
malize the results. The relative protein content was deter-
mined by the density of the resultant bands and expressed
in arbitrary units (AU) relative to the HPRT content, using
Quantity One Software (Bio-Rad).
Immunofluorescent staining
The immunolocalization of the FPr in pCL-MVEC and
pAEC cultures was performed by indirect immunofluores-
cence. Cells grown in slide chambers for 24 h were fixed
with acetone and methanol (1:1; v/v) for 10 min at -20°C
and washed several times with PBS. To better identify the
FPr at the plasma membrane level, immunofluorescent
staining was also performed without previous sample fix-
ation. Slides were blocked with 10 % FBS in PBS for 1 h at
RT and incubated O/N at 4°C with anti-FPr diluted 1:100
in 10 % FBS in PBS or without a primary antibody (nega-
tive control). After several washings in PBS, an FITC-con-
jugated secondary antibody was added (1:800 at RT for 1
h).
The cells were then counterstained with PI and examined
under an epifluorescence microscope equipped with
appropriate filters. A minimum of 100 cells were evalu-
ated for each experimental sample.
PGF2α treatment of pCL-MVECs
pCL-MVECs were grown to confluence (70–80 %) in 8
well slide chambers in HE-SFM (15 % FBS) and then
Table 1: Forward and reverse primer sequences, RT-PCR product length and accession number (Acc.No.) in the EMBL database.
Primer Sequence (5'-3') Product Length (bp) Acc. No.
FPr For.: TCAGCAGCACAGACAAGG
Rev.: TTCACAGGCATCCAGATAATC
151 AY043485
StAR For.: GGACATCCTCAGCAACCAG
Rev.: GTCCACCACCACCTCCAG
121 U53020
HPRT For.: GGACAGGACTGAACGGCTTG
Rev.: GTAATCCAGCAGGTCAGCAAAG
115 AF143818Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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exposed to 10 µg/ml PGF2α (P5069; Sigma) in HE-SFM (1
% FBS) for 6, 12, and 24 hours. pAEC cultures were also
treated with PGF2α as well as with LPS (10 µg/mL for 24 h;
E. coli 055:B5, Sigma) as positive controls. Apoptosis was
determined by the ApopTag Fluorescein in situ apoptosis
detection Kit (S7110, Intergen Company, 10577 NY,
USA), according to the manufacturer's instructions. The
cells were fixed in 1% paraformaldehyde in PBS, post-
fixed in precooled ethanol:acetic acid (2:1, v:v), then incu-
bated with dTT enzyme for digoxigenin dNTP incorpora-
tion (30 min at 37°C) and, after several washings with
DPBS, finally incubated with anti-digoxigenin-fluorescein
antibody (30 min at RT in the dark). The cells were coun-
terstained with PI and observed under an epifluorescence
microscope. A minimum of 200 cells were evaluated for
each experimental point.
Statistical analysis
Data were analyzed by one-way analysis of variance
(ANOVA); the significant differences were analyzed by the
Duncan's test (SPSS Inc, Chicago, IL, USA). A probability
of P < 0.05 was considered significant. Data represent
mean ± SD (n = 4).
Results
Assessment of pCL-MVEC cultures
The functional stages of isolated corpora lutea were con-
firmed by tissue P4 concentrations (26.78 ± 4.2, 48.62 ±
4.1 and 90.43 ± 1.81 ng/mg at EL-, ML- and P-phases,
respectively).
We were able to obtain primary cultures of pCL-MVECs
from all animals. The primary cultures reached confluence
(about 106 cells/flask) in 7.6 ± 2.7 days (min 4, max 12);
all cultures derived from EL-p CLs reached confluence
faster (5 ± 1 days) than ML-p- and P-p-MVECs.
pCL-MVEC cultures showed the typical heterogeneous
morphologies already described for bovine CL-MVEC
[23,39]. Cobble-stone shaped, polygonal opaque, spin-
dle-shaped and phase-dense MVEC phenotypes were
observed (Fig. 1A, B). No evidence of contaminating cells
was observed
Characterization of pCL-MVEC cultures
Identification of the endothelial origin was confirmed by
CD31 and factor VIII immunofluorescence. As expected,
due to the isolation method used, all cells were positively
stained for CD31. The factor VIII distribution varied
among MVEC phenotypes, as reported on bovines [30],
exhibiting a sometimes perinuclear, diffuse or granular
cytoplasmatic pattern while some pCL-MVECs were nega-
tive (Fig. 1C). No fluorescence was detected in the absence
of a primary antibody.
StAR mRNA was not detectable in any pCL MVECs.
Real time quantification of the FPr
FPr mRNA expression was calculated as ∆CT (HPRT CT -
FPr CT). As the HPRT CT were comparable among samples,
increased ∆CT values represent an increase in FPr mRNA
expression.
FPr mRNA expression levels in CL homogenates and in
pCL-MVEC confluent cultures are shown in Fig. 2 and Fig.
3, respectively.
The relative amount of FPr mRNA in luteal tissue signifi-
cantly increased from EL- to ML-, reaching a maximum in
the P-phase (Fig. 2A). FPr mRNA was detectable in all
pCL-MVEC cultures, showing the highest expression in
EL-p derived MVECs; FPr mRNA was also detectable in
pAECs (Fig. 3A).
ML-p pCL-MVECs analysed at different culture times
showed that FPr mRNA was highly expressed in freshly
isolated ML-p pCL-MVEC then the expression was signifi-
cantly reduced after an ON culture and reached the mini-
mum level at confluent stage. The hormonal treatment
had no regulative effect on the expression of FPr mRNA
expression (Fig 4).
Immunodetection of FP receptor
Western blot analysis evidenced a band of molecular
weight (~55 KDa) in both CLs and endothelial cells (Fig.
2C; Fig. 3C). In luteal tissues, the FPr increased from the
EL- to the ML-phase, reaching the highest level during
pregnancy (P-p) (Fig. 2B). Similar levels of FPr in ML- and
P-phase derived pCL-MVECs and in pAECs were observed;
Representative images of mid-uteal-phase porcine corpus  luteum-microvascular endothelial cell (ML-p pCL-MVEC) cul- tures Figure 1
Representative images of mid-uteal-phase porcine corpus 
luteum-microvascular endothelial cell (ML-p pCL-MVEC) cul-
tures. A) pCL-MVECs after 2 days of culture with beads still 
attached (phase contrast microscope ×200). B) the pCL-
MVEC monolayer at confluence (day 7) (phase contrast 
microscope ×100). Different endothelial cell types are 
shown: spindle-shaped cells (black arrowhead), cobble-stone 
cells (white arrow), polygonal-opaque cells (black arrow), 
phase-dense cells (white arrowhead). C) Immunostaining for 
FVIII antigen (epifluorescence microscope ×100).Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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EL-p-derived pCL-MVECs showed a slight but significant
increase in the FPr level (Fig. 3B).
The FPr was diffusely distributed in the cytoplasm of all
pCL-MVECs and in pAECs (Fig. 5A–D). Moreover, P-p
pCL-MVECs showed a clear perinuclear labeling pattern
(Fig. 5C). Positive staining was also observed along the
plasma membrane and was more evident in non-fixed
cells (Fig. 5E). No fluorescence was detected in the
absence of an primary antibody.
Apoptosis detection after PGF2α treatment of pCL-MVEC
PGF2α treatment failed to induce apoptosis in all pCL-
MVEC and pAEC cultures; 30% of the positive controls
(LPS-treated pAECs) showed apoptotic nuclei (Fig. 6).
Discussion
In this study, we describe a reliable method for isolating
and setting up primary cultures of pCL-MVECs. A positive
selection with the employment of anti-CD-31-coupled
magnetic beads was carried out twice. In order to support
the attachment of MVECs, a basal medium optimized for
bovine lung-derived MVECs supplemented with growth
factors (hEGF, VEGF, hFGF, Hydrocortisone) was used
until day 4 of the culture. Rare fibroblasts and parenchy-
mal cells were observed in the culture before applying the
second positive selection procedure. Cells reached conflu-
ence in a specific medium for human endothelial cells
supplemented with 15% FBS. The time required to reach
confluence varied for each pCL-MVEC culture; however,
we observed that EL-p-derived pCL-MVECs proliferated
faster than the others. This was in agreement with the high
mitotic index of ECs observed during CL formation [40-
42]. Confluent pCL-MVEC monolayers showed a hetero-
geneous morphology as documented in bovine CL-
MVECs [23,28]. Various cell phenotypes were present
with a predominance of cobble-stone-like and spindle-
Presence of FPr in porcine corpora lutea-derived microvas- cular endothelial cells (pCL-MVECs) and porcine Aortic  Endothelial Cells (pAECs) Figure 3
Presence of FPr in porcine corpora lutea-derived microvas-
cular endothelial cells (pCL-MVECs) and porcine Aortic 
Endothelial Cells (pAECs). A) Relative FPr mRNA expres-
sion. The results are presented as Delta Ct (HPRT Ct - FPr 
Ct). B) FPr protein content. The results are presented as AU 
(arbitrary units). Data represent mean ± SD. Different letters 
indicate statistically significant differences (P < 0.05). C) Rep-
resentative Western blotting of FPr.
Presence of FPr in porcine corpora lutea (pCLs) at the early- luteal phase (EL-p), the mid-luteal phase (ML-p) and during  pregnancy (P-p) Figure 2
Presence of FPr in porcine corpora lutea (pCLs) at the early-
luteal phase (EL-p), the mid-luteal phase (ML-p) and during 
pregnancy (P-p). A) Relative FPr mRNA expression. The 
results are presented as Delta Ct (HPRT Ct - FPr Ct). B) FPr 
protein content. The results are presented as AU (arbitrary 
units). Data represent mean ± SD. Different letters indicate 
statistically significant differences (P < 0.05). C) Representa-
tive Western blotting of FPr.Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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shaped cells in all pCL-MVECs without any relationship
between the morphological types and CL phases ana-
lyzed, as reported for bovines [39]. The endothelial origin
of the cells was confirmed by traditional endothelial cell
marker expression. Moreover, the absence of StAR mRNA
in the EC cultures indicated the absence of steroidogenic
cell contamination in the confluent MVEC cultures.
FPr expression in CL tissues was found in all the stages
analyzed with an increasing trend from the EL- to the ML-
phase reaching the maximum during pregnancy, both at
mRNA and protein levels in agreement with data already
published for the porcine [3] and the bovine species [43].
Our study documents, for the first time, the presence of
the FPr on MVECs isolated from swine corpora lutea. We
observed that the degree of expression of FPr mRNA var-
ied among the pCL-MVEC cultures in relation to the dif-
ferent CL phases, the highest in the EL-p, decreasing in the
ML-p and reaching its lowest level in the P-phase. At the
protein level, the presence of the FPr was evidenced in all
EC cultures. The amount of FPr protein was very similar
among the MVECs derived from ML-p and P-p CLs and
pAECs, and was significantly higher on MVECs derived
from EL-p CLs. Our data, showing the presence of the FPr
on MVECs at early stages testify to the fact that the refrac-
toriness in this species was not be related to the absence of
the receptor and rather that other mechanisms must be
considered.
The FPr expression level in freshly isolated, overnight and
long-term cultured MVECs, was gradually reduced reach-
ing its minimum value at the confluent stage, in agree-
ment with a recent study [31] showing that ECs modify
their phenotypes when removed from the microenviron-
ment. Nevertheless, in our model, steroid supplementa-
tion (P4  and E2) resembling the in vivo hormonal
environment was not able to regulate FPr expression. Fur-
ther studies may be required to establish if and how cul-
ture conditions may influence FPr expression as well as to
investigate if the receptor is functional on pCL-MVECs.
Effect of PGF2α treatment on apoptosis induction in porcine  corpus luteum-microvascular endothelial cells (pCL-MVECs) Figure 6
Effect of PGF2α treatment on apoptosis induction in porcine 
corpus luteum-microvascular endothelial cells (pCL-MVECs). 
A) Representative images of a TUNEL assay in PGF2α-treated 
mid-luteal phase (ML-p) pCL-MVECs. B) Positive TUNEL 
control (LPS-treated pAECs) (×100).
FPr mRNA expression in porcine corpora lutea-microvascu- lar endothelial cells (pCL-MVECs) freshly isolated (Fresh) and  cultured for different times (overnight-O/N; confluence- Conf.) and in porcine Aortic Endothelial Cells (pAECs) Figure 4
FPr mRNA expression in porcine corpora lutea-microvascu-
lar endothelial cells (pCL-MVECs) freshly isolated (Fresh) and 
cultured for different times (overnight-O/N; confluence-
Conf.) and in porcine Aortic Endothelial Cells (pAECs). The 
confluent stage of the MVECs was reached in the presence 
(+) or absence (-) of hormonal treatment (H = P4 [10-6M] + 
E2 [10-8 M]). The results are presented as Delta Ct (HPRT Ct 
- FPr Ct). The data represent mean ± SD. Different letters 
indicate statistically significant differences (P < 0.05).
Representative FPr immunofluorescent staining on porcine  corpus luteum-microvascular endothelial cells (pCL-MVECs)  isolated from the early luteal phase (EL-p) (A), the mid-luteal  phase (ML-p) (B) and during pregnancy (P-p) (C) (×400) Figure 5
Representative FPr immunofluorescent staining on porcine 
corpus luteum-microvascular endothelial cells (pCL-MVECs) 
isolated from the early luteal phase (EL-p) (A), the mid-luteal 
phase (ML-p) (B) and during pregnancy (P-p) (C) (×400). D) 
porcine Aortic Endothelial Cell (pAEC) culture (x400). Rep-
resentative immunostaining of the FPr on non-fixed EL-p 
pCL-MVECs is shown (E).Reproductive Biology and Endocrinology 2007, 5:31 http://www.rbej.com/content/5/1/31
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The FPr presence on porcine MVECs is in agreement with
data obtained for bovine CLs [7] and contrast with those
obtained for swine CLs in an in situ mRNA study [8], thus
confirming the hypothesis that the discrepancies among
these studies are related to the different techniques used.
Finally, the immunolocalization of the FPr on MVECs
showed positive staining at plasma membrane level as
well as a diffuse perinuclear and cytoplasmatic localiza-
tion in all cultures. Perinuclear FPr immunoreactivity may
be an interaction between the outer membrane of the
nuclei and the endoplasmic reticulum where nascent FP
protein is formed before being transported to the plasma
membrane. The perinuclear staining of P-p CL-MVECs
was more intense than others, suggesting an intensive syn-
thesis/glycosilation of the receptor. All these findings are
consistent with the distribution of the FPr on ECs of
human ocular tissue [44] and on the rat myometrium [45]
as well as other prostaglandin receptors on porcine cere-
bral endothelial cells [46].
In our model, PGF2α  failed to induce an apoptotic
response in all pCL MVEC cultures, in agreement with
other in vitro studies conducted on bovines [30,47]. These
results contrast with in vivo experiments which indicated
endothelial cell apoptosis as an early hallmark of PGF2α-
induced luteal regression in many species [5,6,48]. There-
fore, we can affirm that PGF2α does not directly induce
apoptosis of porcine MVECs in our in vitro model, but the
involvement of other molecules should be investigated
[47,49,50].
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